<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:lptx="http://leaptx.com/20251006">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_lptx_leaptx.com_20251006 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20251006_20251006 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001509745 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000004" name="dei:EntityCentralIndexKey">0001509745</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lptx-20251006.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001509745</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-06</xbrli:startDate>
        <xbrli:endDate>2025-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>UNITED STATES</b></span></p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20251006__20251006_zxuTac4ZhGH8"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_904_edei--DocumentPeriodEndDate_c20251006__20251006_ziPjKwHryKU9"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 6, 2025</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20251006__20251006_z3lPn3hsofKj"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000011" name="dei:EntityRegistrantName">Leap Therapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20251006__20251006_zIwLJw2PdN57"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20251006__20251006_zRgC1KgkgBq2"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000013" name="dei:EntityFileNumber">001-37990</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20251006__20251006_zuZPNh3VasF5"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-4412575</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/> of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">(Commission <br/>
File Number)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer<br/>
Identification No.)</td></tr>
</table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20251006__20251006_zQMxabO6xr09"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000015" name="dei:EntityAddressAddressLine1">47 Thorndike Street</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20251006__20251006_zvcB71XnAn7c"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite B1-1</ix:nonNumeric></span></b></span> <br/> <span style="background-color: white"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20251006__20251006_zP7glLJorM85"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000017" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20251006__20251006_zTnSAERvDEmi"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b></span> <span style="font-size: 10pt; background-color: white"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20251006__20251006_z24kERg9oHsh"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000019" name="dei:EntityAddressPostalZipCode">02141</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">(Address of Principal Executive Office)</span> <span style="font-size: 10pt">(Zip Code)</span></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <b>(<span id="xdx_90A_edei--CityAreaCode_c20251006__20251006_zYRYUBDkdz09"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000020" name="dei:CityAreaCode">617</ix:nonNumeric></span>)&#160;<span id="xdx_90E_edei--LocalPhoneNumber_c20251006__20251006_zCTxbWZVLpyi"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000021" name="dei:LocalPhoneNumber">714-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant&#8217;s telephone
number, including area code)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_90B_edei--WrittenCommunications_c20251006__20251006_zuhXoO1qWCIb" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_90B_edei--SolicitingMaterial_c20251006__20251006_zUp4kqX8v4pa" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_907_edei--PreCommencementTenderOffer_c20251006__20251006_z5Jufs57vIil" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20251006__20251006_zCeXO509BPk6" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20251006__20251006_zBym17xzMgl4"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20251006__20251006_zHx9buhYJhP9"><ix:nonNumeric contextRef="AsOf2025-10-06" id="Fact000027" name="dei:TradingSymbol">LPTX</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-size: 10pt">The <span id="xdx_907_edei--SecurityExchangeName_c20251006__20251006_zQhz2RzjSzMc"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &#167;240.12b-2).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20251006__20251006_zYb2XxFZBYp3"><ix:nonNumeric contextRef="AsOf2025-10-06" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry Into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><i>Securities Purchase Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2025, Leap Therapeutics, Inc., a
Delaware corporation (the &#8220;<b>Company</b>&#8221;), entered into a Securities Purchase Agreement (the &#8220;<b>Securities Purchase
Agreement</b>&#8221;) with the investors named therein (the &#8220;<b>Purchasers</b>&#8221;), for the private placement (the &#8220;<b>Private
Placement</b>&#8221;) of (i) an aggregate of 15,212,311 shares (the &#8220;<b>Shares</b>&#8221;) of common stock of the Company, par value
$0.001 per share (the &#8220;<b>Common Stock</b>&#8221;), at an offering price of $0.52064 per share, (ii) pre-funded warrants (the &#8220;<b>Pre-Funded
Warrants</b>&#8221;) to purchase up to an aggregate of 80,768,504 shares of Common Stock (the &#8220;<b>Pre-Funded Warrant Shares</b>&#8221;)
at an offering price of $0.51964 per Pre-Funded Warrant, each exercisable for one share of Common Stock at the exercise price of $0.001
per Pre-Funded Warrant Share, and (iii) common warrants (the &#8220;<b>Common Warrants</b>&#8221; and together with the Shares and Pre-Funded
Warrants, the &#8220;<b>Securities</b>&#8221;) to purchase up to an aggregate of 71,985,605 shares of Common Stock (the &#8220;<b>Common
Warrant Shares</b>&#8221;), each exercisable for one share of Common Stock at the exercise price of $0.5335 per Common Warrant Share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Placement closed on October 8, 2025
(the &#8220;<b>Closing Date</b>&#8221;). The aggregate gross proceeds of the Private Placement were approximately USD $58.88 million,
before deducting fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants are exercisable in cash or
by means of a cashless exercise. They will expire on the tenth anniversary of their date of issuance. The exercise price and the number
of shares of Common Stock issuable upon exercise of each Common Warrant is subject to appropriate adjustment in the event of certain stock
dividends, stock splits, stock combinations, or similar events affecting the Common Stock. The Common Warrants may not be exercised if
the aggregate number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following
such exercise would exceed a specified beneficial ownership limitation&#894; provided, however, that a holder may increase or decrease
the beneficial ownership limitation by giving notice to the Company (with 61 days&#8217; notice required for increases), but not to any
percentage in excess of 19.99%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants are exercisable in cash
or by means of a cashless exercise and will not expire until the date such Pre-Funded Warrants are fully exercised. The unfunded exercise
price of each Pre-Funded Warrant will equal $0.001 per underlying Pre-Funded Warrant Share. The exercise price and the number of shares
of Common Stock issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends,
stock splits, stock combinations, or similar events affecting the Common Stock. The Pre-Funded Warrants may not be exercised if the aggregate
number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise
would exceed a specified beneficial ownership limitation&#894; provided, however, that a holder may increase or decrease the beneficial
ownership limitation by giving notice to the Company (with 61 days&#8217; notice required for increases), but not to any percentage in
excess of 19.99%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds from
the Private Placement for its recently announced digital asset treasury strategy, pursuant to which the Company plans to pursue a number
of strategic initiatives involving investment in tokens and digital asset treasury activities. The Company will also use
a portion of the proceeds to continue development of the Company&#8217;s therapeutic programs, including FL-501 and sirexatamab, as well
as to pay the transaction costs and fees, and for working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities Purchase Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company,
other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Securities Purchase Agreement,
the Company has agreed to certain restrictions on the issuance and sale of the Company&#8217;s securities for a period beginning on the
date of the Securities Purchase Agreement until the thirtieth (30th) day following the Closing Date, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parcrest International (&#8220;<b>Parcrest</b>&#8221;)
has agreed to serve as the Company&#8217;s placement agent in connection with the Private Placement. The Company has agreed to pay Parcrest
$1.5 million, of which $1.0 million will be paid in cash and the remainder in the form of warrants (the &#8220;<b>Placement Agent Warrants</b>&#8221;),
which shall be of the same series and have the same terms as the Common Warrants, to purchase up to 4,000,000 shares of Common Stock.
The Placement Agent has agreed that it shall not sell, transfer, assign, pledge, or otherwise dispose of any of the Placement Agent Warrants
or the warrant shares underlying the Placement Agent Warrants for a period of six (6) months following their issuance date, except with
the prior written consent of both the Company and the Lead Investor (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities to be issued pursuant to the Securities
Purchase Agreement have not been registered under the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;), or
any state securities laws and will be issued pursuant to the exemption from registration provided for under Section 4(a)(2) of the Securities
Act and/or Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Company
relied on this exemption from registration based in part on representations made by the Purchasers. The Securities may not be offered
or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current Report
on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><i>Registration Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated October 6,
2025 (the &#8220;<b>Registration Rights Agreement</b>&#8221;), providing for the registration for resale of the Shares, the Common Warrant
Shares, and the Pre-Funded Warrant Shares on an effective registration statement, pursuant to a registration statement (the &#8220;<b>Resale
Registration Statement</b>&#8221;) to be filed with the U.S. Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) no later
than thirty (30) days following the written demand by any Purchaser. The Company has agreed to use commercially reasonable efforts to
cause the Resale Registration Statement to be declared effective as promptly as possible, but in no event later than the tenth (10th)
calendar day following its filing date, or, in the event of a review by the SEC, the seventy-fifth (75</span><span style="font-size: 10pt">th</span>)
calendar day following the filing date (provided, that if the SEC is closed for operations due to a government shutdown, the effectiveness
date shall be extended by the same number of trading days on which the SEC remains closed), and to keep the Resale Registration Statement
continuously effective from the date on which the SEC declares the Resale Registration Statement to be effective until (i) the date on
which the Purchasers shall have resold or otherwise disposed of all the Registrable Securities (as such term is defined in the Registration
Rights Agreement) covered thereby, or (ii) the date on which the Registrable Securities may be resold by the Purchasers without registration
and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in
compliance with the current public information requirement under Rule 144 or any other rule of similar effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has granted the Purchasers customary
indemnification rights in connection with the Registration Rights Agreement. The Purchasers have also granted the Company customary indemnification
rights in connection with the Registration Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22.5pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions of the Securities Purchase
Agreement, Registration Rights Agreement, the Common Warrants and the Pre-Funded Warrants are not complete and are qualified in their entirety
by reference to the forms of Securities Purchase Agreement, Registration Rights Agreement, Common Warrant and Pre-Funded Warrant, which
are filed as Exhibits 10.1, 10.2, 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0; text-align: justify"><i>Lead Investor Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30pt 0pt 15.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2025, the Company entered into
a Lead Investor Agreement (the &#8220;<b>Lead Investor Agreement</b>&#8221;) with Winklevoss Treasury Investments, LLC (the
&#8220;<b>Lead Investor</b>&#8221;) to secure the commitment of the Lead Investor in the Private Placement. Pursuant to the Lead
Investor Agreement, as of the Closing Date, the Board of Directors of the Company (the &#8220;<b>Board</b>&#8221;) increased the
size of the Board to twelve members and, subject to applicable corporate governance requirements, has granted the Lead Investor the right
to nominate two directors to the Board to fill the vacancies (the &#8220;<b>Investor Designees</b>&#8221;), one of whom shall act as
chair of the Board. From and after the Closing Date, so long as the Lead Investor continues to beneficially own at least 16.7% of
the Common Stock, the Lead Investor shall have the right to designate two Investor Designees, one of whom shall also be chair
of the Board, and for so long as the Lead Investor continues to beneficially own at least 8.33% but less than 16.7% of the Common
Stock, the Lead Investor shall have the right to designate one Investor Designee, who shall also be the chair of the Board.
The Company has agreed to use its reasonable best efforts to cause the Investor Designees to be elected to the Board (including
recommending that the Company&#8217;s stockholders vote in favor of the election of the Investor Designees). The Lead Investor
Agreement also contains customary representations and warranties, confidentiality provisions and limitations on liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Lead Investor
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lead Investor Agreement,
a copy of which is attached hereto as Exhibit 10.3, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in Item 1.01 of this
Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form 8-K nor any exhibit attached hereto
is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2025, the Company issued a press
release announcing the Closing of the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this Item 7.01, including
Exhibit 99.1, is deemed to have been furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange
Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;), or otherwise subject to the liabilities of that section, and is not incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K includes forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements
generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221;
and other words of similar meaning. These forward-looking statements address various matters including statements relating to the anticipated
benefits and timing of the completion of the Private Placement and related transactions, the intended use of proceeds from the Private
Placement, the assets to be held by the Company, the expected future market, price and liquidity of the digital assets the Company acquires,
the macro and political conditions surrounding digital assets, the Company&#8217;s plan for value creation and strategic advantages, market
size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business
strategies, technological and market trends, future financial condition and performance and the expected financial impacts of the proposed
transactions described herein. Each forward-looking statement contained in this Current Report on Form 8-K (and the associated exhibits
attached hereto) is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied
by such statement. Applicable risks and uncertainties include, among others, the risk that the Private Placement may not be completed
in a timely manner or at all; failure to realize the anticipated benefits of the transactions and the proposed digital asset treasury
strategy; changes in business, market, financial, political and regulatory conditions; risks relating to the Company&#8217;s operations
and business, including the highly volatile nature of the price of cryptocurrencies; the risk that the price of the Company&#8217;s Common
Stock may be highly correlated to the price of the digital assets that it holds; risks related to increased competition in the industries
in which the Company does and will operate; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding
digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; as well as those risks and
uncertainties identified under the heading &#8220;Item 1A. Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the
fiscal year ended December 31, 2024, filed with the SEC on March 26, 2025 and other information the Company has or may file with the SEC,
including those disclosed under Item 8.01 of this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We caution investors not to place considerable
reliance on the forward-looking statements contained in this Current Report on Form 8-K (and the associated exhibits attached hereto).
You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these
statements except as required by applicable law. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2528058d2_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2528058d2_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant </span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2528058d2_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2528058d2_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2528058d2_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead Investor Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2528058d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2528058d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated October 9, 2025</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 50%">&#160;</td>
    <td style="text-align: justify; width: 50%"><b>LEAP THERAPEUTICS, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Date: October 9, 2025</td>
    <td style="border-bottom: black 1pt solid; text-align: justify">/s/ Douglas E. Onsi</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Douglas E. Onsi</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">President &amp; CEO</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZiyahLuzSoiJWkSLiNthRgm2mTGLVI3lLY4s4DAzD/+9/IUZiRUtbI8NpXhZwwKatTUAo8YKM7ozRka83GcRb4tX6wMaF/v2BOUUGIzMda22i0Fs767HKQKYTJSc6BTnLlIL9ViRfPSd3sRW6YE0NxlWwZ2rZYjD8GhIO5kmOmldfdUT2llwGaiwH+Q1aKg076syD+OahKHKRjPpJxIrp3kbX4hnQfUlY1NjEOj/Q/00+A8hKiA== -->
</body>
</html>
